{"disease":{"id":"cgvhd","name":"cgvhd"},"drugs":{"marketed":[{"drug_id":"axatilimab","indication_name":"chronic graft-versus-host disease (cGVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niktimvo","generic_name":"AXATILIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Colony Stimulating Factor-1 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00128973","title":"Evaluation of Patients With Immune Function Abnormalities","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05919511","title":"Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06364319","title":"Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07271498","title":"The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06186804","title":"A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":64,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT05873907","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05214066","title":"Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07246031","title":"BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"BioPhoenix Co., Ltd.","has_results":false},{"nct_id":"NCT06663722","title":"Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT07253259","title":"A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT07476872","title":"Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03422627","title":"Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06991361","title":"Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Leslie Kean","has_results":false},{"nct_id":"NCT06244628","title":"Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Xuzhou Medical University","has_results":false},{"nct_id":"NCT06920199","title":"Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05885451","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06458127","title":"Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05604742","title":"Belimumab for Treatment of cGVHD Following Allo-HCT","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"xuna","has_results":false},{"nct_id":"NCT04745637","title":"Managed Access Programs for INC424, Ruxolitinib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}